Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.30 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308797 | 0.87 | HTR7 (0.39) | MCHR1CYP11B1CYP11B2 | |
| SCHEMBL308516 | 0.80 | IDO1 (0.40) | MCHR1 | |
| SCHEMBL7128104 | 0.79 | MET (0.35) | NPC1RAB9AKMT2ATDP1MAP3K8 | |
| SCHEMBL7127635 | 0.73 | EGFR (0.55) | — | |
| SCHEMBL5240858 | 0.70 | ALDH1A1 (0.40) | NPC1RAB9AKMT2ATDP1MCHR1 | |
| SCHEMBL7673525 | 0.68 | RAB9A (0.33) | NPC1RAB9AKMT2ATDP1MAP3K8 | |
| SCHEMBL5242191 | 0.68 | CDC7 (0.43) | NPC1RAB9AKMT2ATDP1MAP3K8 | |
| SCHEMBL308582 | 0.68 | MAP3K8 (0.51) | NPC1RAB9AKMT2ATDP1MAP3K8 | |
| SCHEMBL3566336 | 0.68 | MCHR1 (0.32) | NPC1RAB9AMCHR1 | |
| SCHEMBL5240748 | 0.67 | ADORA1 (0.40) | NPC1RAB9AKMT2ATDP1MAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | NPC1 2221/4885RAB9A 2707/4885KMT2A 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.